PAA 0.00% 19.5¢ pharmaust limited

Ann: Motor Neurone Disease Clinical Trial Update, page-111

  1. 1,840 Posts.
    lightbulb Created with Sketch. 2226
    And on the dog side, similar things.

    we all know it has taken, what feels like a life time, to get only part way to the official end point of the trial

    we all know that statistically it is extremely challenging to see 18 dogs with stable disease by mid year

    we all know dogs, on average, are living longer regardless of being stable or progressive

    we all know the ability to treat at home and with a very safe drug is a standout in this field

    we all know that quality of life is measurably better for the duration of the time the dogs live

    we all know that more vets have come onboard recently with inclusion of Thrive in the good ole US of A

    we all know Dr Kim is confident of closing Phase 2 mid year but as mentioned above, challenging to see the official phase 2 end point met.

    we all know they are going to head to phase 3

    we all know it will not just be MPL , it will be in combo with prednisolone


    My bet is on Thrive (aka Pet Care Major - PCM) are excited

    so my optimism is not about hitting 18 dogs with stable disease, rather the proportion that live longer, have better QoL and with a safe / at home treatment that does not require extreme expensive specialty equipment or specialist vets is of huge interest to someone in the PCM game to take on a competitive edge to others in the USA vet market.

    gee, I really am optimistic today.
    Last edited by adreamer: 02/06/23
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
19.5¢
Change
0.000(0.00%)
Mkt cap ! $86.55M
Open High Low Value Volume
19.5¢ 19.5¢ 18.5¢ $330.4K 1.741M

Buyers (Bids)

No. Vol. Price($)
1 4071 19.0¢
 

Sellers (Offers)

Price($) Vol. No.
19.5¢ 24580 3
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.